Patents by Inventor Nadav BLEICH KIMELMAN

Nadav BLEICH KIMELMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOF
    Publication number: 20240148653
    Abstract: The present invention provides parenteral pharmaceutical compositions including therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.
    Type: Application
    Filed: December 19, 2023
    Publication date: May 9, 2024
    Applicant: Mapi Pharma Ltd.
    Inventors: Galina ZATS, Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
  • Semaglutide depot systems and use thereof
    Patent number: 11865213
    Abstract: The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: January 9, 2024
    Assignee: MAPI PHARMA LTD.
    Inventors: Galina Zats, Nadav Bleich Kimelman, Shai Rubnov, Ehud Marom
  • LOW BURST-RELEASE LIRAGLUTIDE DEPOT SYSTEMS
    Publication number: 20230256058
    Abstract: The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of liraglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release in the first twenty-four hours post administration. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus and Parkinson's disease.
    Type: Application
    Filed: April 26, 2021
    Publication date: August 17, 2023
    Applicant: MAPI PHARMA LTD.
    Inventors: Galina ZATS, Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
  • SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOF
    Publication number: 20230014750
    Abstract: The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.
    Type: Application
    Filed: November 24, 2021
    Publication date: January 19, 2023
    Applicant: Mapi Pharma Ltd.
    Inventors: Galina ZATS, Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
  • PROCESS FOR PREPARING MICROPARTICLES CONTAINING GLATIRAMER ACETATE
    Publication number: 20230000782
    Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.
    Type: Application
    Filed: September 2, 2022
    Publication date: January 5, 2023
    Applicant: MAPI PHARMA LTD.
    Inventors: Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
  • Process for preparing microparticles containing glatiramer acetate
    Patent number: 11471421
    Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: October 18, 2022
    Assignee: MAPI PHARMA LTD.
    Inventors: Nadav Bleich Kimelman, Shai Rubnov, Ehud Marom
  • Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
    Patent number: 11413311
    Abstract: Methods of treating multiple sclerosis are provided, comprising parenterally administering glatiramer acetate in a sustained-release depot form, and administering adipose-derived stem cells into the central nervous system. According to some aspects the combined treatments provide synergistic effects. In particular the combined therapies offer benefits to progressive forms of multiple sclerosis.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: August 16, 2022
    Assignees: MAPI PHARMA LTD., STEM CELL MEDICINE LTD.
    Inventors: Ehud Marom, Nadav Bleich Kimelman, Frida Grynspan
  • GLATIRAMER DEPOT SYSTEMS FOR TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
    Publication number: 20220023377
    Abstract: The present invention provides methods for treating or ameliorating primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) and related symptoms by administering or implanting a depot formulation comprising glatiramer salts, such as glatiramer acetate (GA).
    Type: Application
    Filed: October 6, 2021
    Publication date: January 27, 2022
    Applicant: MAPI PHARMA LTD.
    Inventors: Uri DANON, Nadav BLEICH KIMELMAN, Laura POPPER, Ehud MAROM
  • Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
    Patent number: 11167003
    Abstract: The present invention provides methods for treating or ameliorating primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) and related symptoms by administering or implanting a depot formulation comprising glatiramer salts, such as glatiramer acetate (GA).
    Type: Grant
    Filed: March 25, 2018
    Date of Patent: November 9, 2021
    Assignee: MAPI PHARMA LTD.
    Inventors: Uri Danon, Nadav Bleich Kimelman, Laura Popper, Ehud Marom
  • PROCESS FOR PREPARING MICROPARTICLES CONTAINING GLATIRAMER ACETATE
    Publication number: 20210299057
    Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.
    Type: Application
    Filed: August 28, 2017
    Publication date: September 30, 2021
    Applicant: MAPI PHARMA LTD.
    Inventors: Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
  • DEPOT SYSTEMS COMPRISING GLATIRAMER ACETATE
    Publication number: 20210283209
    Abstract: The present invention provides compositions and methods of use thereof for treating or ameliorating multiple sclerosis (MS) by administering a depot formulation comprising 40 mg glatiramer acetate intramuscularly to the MS patient.
    Type: Application
    Filed: August 9, 2017
    Publication date: September 16, 2021
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud MAROM, Nadav BLEICH KIMELMAN, Uri DANON, Shai RUBNOV
  • TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH LONG ACTING GLATIRAMER AND ADIPOSE-DERIVED STEM CELLS
    Publication number: 20210220428
    Abstract: Methods for treating inflammatory bowel disease are provided, comprising administration of glatiramer acetate in a sustained-release depot form and administration of adipose-derived stem cells.
    Type: Application
    Filed: June 29, 2017
    Publication date: July 22, 2021
    Applicants: STEM CELL MEDICINE LTD., MAPI PHARMA LTD.
    Inventors: Ehud MAROM, Nadav BLEICH KIMELMAN, Frida GRYNSPAN
  • GLATIRAMER DEPOT SYSTEMS FOR TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
    Publication number: 20200376069
    Abstract: The present invention provides methods for treating or ameliorating primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) and related symptoms by administering or implanting a depot formulation comprising glatiramer salts, such as glatiramer acetate (GA).
    Type: Application
    Filed: March 25, 2018
    Publication date: December 3, 2020
    Applicant: MAPI PHARMA LTD.
    Inventors: Uri DANON, Nadav BLEICH KIMELMAN, Laura POPPER, Ehud MAROM
  • TREATMENT OF MULTIPLE SCLEROSIS WITH LONG ACTING GLATIRAMER AND ADIPOSE-DERIVED STEM CELLS
    Publication number: 20200147141
    Abstract: Methods of treating multiple sclerosis are provided, comprising parenterally administering glatiramer acetate in a sustained-release depot form, and administering adipose-derived stem cells into the central nervous system. According to some aspects the combined treatments provide synergistic effects. In particular the combined therapies offer benefits to progressive forms of multiple sclerosis.
    Type: Application
    Filed: May 15, 2017
    Publication date: May 14, 2020
    Applicants: STEM CELL MEDICINE LTD., MAPI PHARMA LTD.
    Inventors: Ehud MAROM, Nadav BLEICH KIMELMAN, Frida GRYNSPAN
  • Sublingual delivery of glatiramer acetate
    Patent number: 10493122
    Abstract: The present invention provides Glatiramer acetate compositions in a non-gelling matrix, formulated for sublingual delivery.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: December 3, 2019
    Assignee: MAPI PHARMA LTD.
    Inventors: Yoram Sela, Ehud Marom, Nadav Bleich Kimelman
  • SUBLINGUAL DELIVERY OF GLATIRAMER ACETATE
    Publication number: 20170080044
    Abstract: The present invention provides Glatiramer acetate compositions in a non-gelling matrix, formulated for sublingual delivery.
    Type: Application
    Filed: March 16, 2015
    Publication date: March 23, 2017
    Applicant: MAPI PHARMA LTD.
    Inventors: Yoram SELA, Ehud MAROM, Nadav BLEICH KIMELMAN